View Older Stories
-
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
-
Defence Therapeutics appoints Dr. Sarkis Meterissian to advisory board
-
Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
-
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
-
Defence Therapeutics Announces Grant of Restricted Stock Units
-
Defence Therapeutics Announces Warrant Terms Amendment
-
Defence Therapeutics closes $9.6 million private placement
-
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
-
Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
-
Defence Therapeutics announces private placement for up to $11 million
-
Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million
-
Defence Therapeutics refines ADC strategy with advisory board input
-
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
-
Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform
-
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
-
Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
-
Defence Therapeutics Announces AGM Results and Provides Corporate Updates
-
Defence Therapeutics forms scientific advisory board for ADC programs
-
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
-
Defence Therapeutics Announces Convertible Debenture Conversion
-
Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology
-
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
-
Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models
-
Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
-
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
-
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
-
Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin
-
Defence Therapeutics names Dr. Amie Phinney to board of directors
-
Defence Therapeutics Appoints Dr. Amie Phinney as Director
-
Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000
-
Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
-
Defence Therapeutics Announces Debenture Units Financing
-
Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer
-
Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology
-
Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
-
Defence Therapeutics to Attend Bio International Convention in Boston, June 2025
-
Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies
-
Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence's Management Team as Chief Operating Officer
-
Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million
-
Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025
-
Defence Fortifies Patent Portfolio
-
Defence Arranges Financing
-
Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors
-
Defence Provides Update on Delivery of AGSM Proxy Materials
-
Defence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)
-
Defence Announces Dr. Maxime Parisotto as CSO, Director of Science and Business Development
-
Defence Announces Closing of Securities for Debenture Financing
-
Defence Therapeutics Announces Securities for Debenture Financing
-
Defence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of Directors
-
Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs
